Cylene to Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, at International CK2 Conference
Cylene's CX-4945 to be recognized as the only clinical stage CK2 inhibitor for multiple cancers
SAN DIEGO, Sept. 8 /PRNewswire/ -- Cylene Pharmaceuticals, Inc.
will report recent developments with its first-in-class, oral CK2
inhibitor CX-4945, at the 6th International Conference on Protein
Kinase CK2, to be held on September 7-10 in Cologne, Germany, the
company announced today. CX-4945 is potentially a dynamic
anticancer therapeutic, as both a stand-alone drug and for use in
combination therapies. The meeting will be attended by leading CK2
experts and will emphasize the importance of CK2 in many aspects of
biology and human disease.
At the conference Cylene scientists will discuss the discovery
and development of CX-4945, the first potent and selective
inhibitor of protein kinase CK2. A symposium presentation and
posters will outline the chemistry expertise that enabled Cylene to
rationally design CX-4945, as well as the novel biology that has
guided its development. CK2 is crucial to the development and
maintenance of key cancer processes and, as the first clinical CK2
inhibitor, CX-4945 provides an innovative and exciting weapon in
the fight against cancer. Specifically, CK2 plays critical roles in
the DNA Damage Response, PI3K/Akt and EGF-Receptor pathways,
thereby providing a strong mechanistic rationale for the
synergistic combination of CX-4945 with many agents that target
these same pathways for the treatment of multiple cancers.
"The scientific understanding of CK2 and its multiple roles in
cancer cell survival has emerged from the fundamental research
performed by scientists attending the International CK2 Conference.
Cylene has built upon this knowledge and now has the only clinical
stage CK2 inhibitor. We are thrilled with the performance of
CX-4945 in the clinic to date and anticipate delivering real
benefit to patients in our continuing Phase I and Phase II trials,"
commented William Rice, PhD, President and CEO of Cylene
About CK2 and CX-4945
Protein kinase CK2 has emerged as a validated drug target for
cancer therapy due to its dysregulation and overexpression in
tumors and its regulatory roles in cell cycle control, DNA damage
repair, and in the PI3K/Akt, Wnt and NFkB signaling cascades.
CX-4945 is a potent and highly selective, small molecule inhibitor
of CK2 and is currently under evaluation as an orally administered
single agent in a Phase I clinical trial in patients with solid
tumors (including breast, prostate, pancreatic cancers and
inflammatory breast cancer, as well as multiple myeloma and
Castleman's Disease). During this trial, CX-4945 has established
favorable pharmacokinetic, pharmacodynamic and safety profiles.
Measurement of mechanism and tumor-related biomarkers in patients
reveal that CX-4945 hits the CK2 target and down-modulates the
PI3K/Akt pathway. The pharmacokinetic and biomarker data
demonstrate that CX-4945 is achieving pharmacologically active
levels in plasma and in tumor cells and elicits a clear
pharmacodynamic response in humans. Together, the findings
establish CX-4945 as a promising therapeutic agent for targeting
About Cylene Pharmaceuticals
Cylene Pharmaceuticals, Inc. is a San Diego-based, private
biotechnology company discovering and developing targeted small
molecule drugs to treat life-threatening cancers. Cylene's drug
discovery platform, STAND (Selective TArgeting of Non-Oncogene
Networks in Disease), has delivered a diverse portfolio of drug
candidates that target the multiple pathways critical for the
support and maintenance of cancer cells and that address unmet
medical needs with substantial markets. Cylene's novel agents
include oral inhibitors of the cancer-linked serine/threonine
protein kinases (CK2 and Pim), as well as oral agents that activate
p53 via modulation of RNA Polymerase I activity in the upstream
ribosome biogenesis pathway. Cylene's innovative platform enables
the rapid discovery of first-in-class agents that exert antitumor
activity as a single agent and that can mechanistically enhance the
effectiveness of current cancer therapies. For more information on
Cylene and its programs, please visit www.cylenepharma.com.
Source: Cylene Pharmaceuticals, Inc.
CONTACT: Sean O'Brien, PhD, Director of Research and
Development of Cylene Pharmaceuticals, Inc., +1-858-875-5100 , Fax,
Web Site: http://www.cylenepharma.com/
Posted: September 2010